Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Acurx Pharmaceuticals' stock, indicating it has good growth potential.
Financial Health
Acurx Pharmaceuticals shows strong cash flow and a solid book value per share, indicating good financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ACXP
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Micro‑cap market dynamics
A small market capitalisation often means higher volatility and lower liquidity; this creates both potential opportunity and increased risk, so position sizing is important.
Pipeline outcomes matter
Clinical or regulatory news can trigger significant share moves; positive data may boost prospects, while negative results can be materially damaging.
Funding and strategic partners
Early‑stage companies commonly rely on fundraising or licensing partnerships; review the balance sheet and financing plans because future dilution is a common risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
